October 6, 2008
Warsaw Blood Center Selects CaridianBCT for Mirasol(R) Pathogen Reduction Technology
CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies, announced today that one of the largest blood centers in Poland, Warsaw Blood Center, has entered into a multi-year agreement to purchase the Mirasol Pathogen Reduction Technology (PRT) system for platelets.
The Mirasol PRT system is a groundbreaking new technology that reduces the active pathogen load and inactivates residual white blood cells in donated blood components for transfusion. The system uses riboflavin (vitamin B2) and a specific spectrum of ultraviolet light to alter the nucleic acids of pathogens and white blood cells found in donated blood components, rendering them inactive and unable to replicate."At the RCKiK blood bank in Warsaw, we are continuously striving to supply excellent quality and safe blood products to our hospitals, as well as, to keep our staff motivated and happy. The Mirasol PRT system, therefore, matches our goals well. It reduces pathogens in a very simple, fast and efficient way. We are excited to introduce this innovative technology in our center to treat our platelet products," said Dariusz Piotrowski, Director of the RCKiK blood bank in Warsaw.
A unique feature of the Mirasol PRT system is its use of a safe, naturally-occurring compound that has been shown to be non-toxic and non-mutagenic. The residual riboflavin or any photoproducts produced during the process do not need to be removed prior to transfusion and do not present any toxicity risks for either the blood handler or the patient. Additionally, the system is easy to use and designed to fit into current blood bank operations.
"The adoption of our Mirasol PRT system by the Warsaw Blood Center demonstrates our shared vision of improving lives through better blood," said CaridianBCT President and Chief Executive Officer David B. Perez. "As the first public tender issued and awarded since the Mirasol PRT system received its CE Mark nine months ago, this significant milestone reflects our commitment to providing customers, and the patients they serve, new innovations to increase the safety of the world's blood supply."
Developed by CaridianBCT Biotechnologies, LLC, the system has been under extensive scientific research, development and testing since 1999 and has been evaluated for its effectiveness against a broad range of disease-causing agents, including viruses, bacteria, parasites and white blood cells. Most recently, the safety and efficacy of the system has been demonstrated in a multi-center clinical evaluation in thrombocytopenic patients. The system has been shown to substantially reduce the active pathogen load and effectively inactivate residual white blood cells that may be present in donated blood components. The technology also allows rapid release of platelets after illumination, as no removal of the active ingredient, riboflavin, is required due to its safety profile.
The Mirasol PRT system recently received a CE mark for use with fresh frozen plasma and is available for sale in countries where the CE mark is accepted. It is not, however, available for sale in the United States.
CaridianBCT Biotechnologies, LLC is wholly owned subsidiary of CaridianBCT, Inc. CaridianBCT, Inc. improves lives through innovation, quality and services delivered by its people, products and processes in blood component technology. It is a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies--serving blood banks, hospitals and clinical and biotech research facilities. Headquartered in Lakewood, CO., the company has global operations in 32 countries and employs more than 2500 people. For more information, visit www.caridianbct.com.